Ennaid Therapeutics | Ennaid Therapeutics Prioritizes Zika Virus Rapid Drug Development in Wake of Crisis
19194
post-template-default,single,single-post,postid-19194,single-format-standard,ajax_fade,page_not_loaded,,qode-theme-ver-7.7,wpb-js-composer js-comp-ver-5.2.1,vc_responsive

Ennaid Therapeutics Prioritizes Zika Virus Rapid Drug Development in Wake of Crisis

15 Feb Ennaid Therapeutics Prioritizes Zika Virus Rapid Drug Development in Wake of Crisis

ALPHARETTA, Ga.Feb. 14, 2016 /PRNewswire/ — Ennaid Therapeutics, located in Alpharetta, GA is developing therapeutic cures to help the millions of people worldwide when infected with the mosquito-borne disease, Zika Virus, now named a global public health emergency by the World Health Organization and the CDC. The global health community is urging caution and care in response to Zika’s explosive spread and is calling for rapidly stepped up efforts by researchers to find therapeutics and vaccines for those who contract it.

For years, Ennaid Therapeutics has been committed to developing cures for mosquito-borne diseases, including Dengue, Chikungunya and Zika viruses – and is now advancing its work on Zika to address the urgent global need.

Zika Virus

Zika is linked to microcephalic birth defects and possible eye damage in babies. The virus, which is transmitted by Aedes species mosquito, has infected 1 million Brazilians and 50+ people in the United States. An estimated 4 million infections are expected in the Americas in 2016. Zika’s risk to pregnant women is a top priority, according to the CDC.

“Zika virus, which is now our focus, has been in our ten-product pipeline for years, and we will continue developing cures for the growing numbers of Dengue, West Nile and Chikungunya sufferers, among other mosquito-borne diseases,” says Darnisha Harrison, Ennaid Therapeutics’ CEO.

Please see link below of Discovery Channel’s Innovations with Ed Begley, Jr., in which Ennaid Therapeutics will be featured: http://www.prweb.com/releases/2015/10/prweb13028491.htm.

 

Read More . . . 

No Comments

Sorry, the comment form is closed at this time.